![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-4.50 | -0.28% | 1,600.00 | 1,598.00 | 1,599.00 | 1,613.00 | 1,589.00 | 1,613.00 | 3,788,149 | 16:35:01 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.35 | 65.81B |
Date | Subject | Author | Discuss |
---|---|---|---|
19/12/2019 14:59 | But couldn't that take up to 2-3 years, yet? | tradermichael | |
19/12/2019 14:50 | This may be due to Pfizer & GSK oncoming health division merger . | abdullla | |
19/12/2019 14:35 | This has continued through the afternoon. Good underlying momentum in the share price now …. ;0) | tradermichael | |
19/12/2019 12:27 | Share trades volume has been strong this morning … ;0) | tradermichael | |
19/12/2019 08:50 | "Benlysta is the only biologic approved specifically for lupus and has moved slowly but surely toward blockbuster sales in the indication. In the first nine months of 2019, Benlysta posted $581 million in worldwide sales, a 32% jump from the same time period last year. Adding an indication could boost the drug's sales even further, with about 60% of 328,000 severe U.S. lupus patients suffering from lupus nephritis each year," GSK said. | tradermichael | |
18/12/2019 16:03 | "Glaxo's Benlysta successful in lupus nephritis study" GlaxoSmithKline (GSK +0.3%)&nbs The study met the primary endpoint showing a statistically significantly greater proportion of patients treated with Benlysta + standard-of-care (SOC) therapy achieving renal response at week 104 compared to those receiving placebo + SOC (43% vs. 32%, p=0.0311). | ![]() crossing_the_rubicon | |
18/12/2019 09:18 | Very pleasing move up and new high Undoubtedly benefiting a bit from pound weakness but more to come me thinks | ![]() panshanger1 | |
18/12/2019 09:15 | Ms Walmsley rubbing things up the right way | ![]() purplepelmets | |
18/12/2019 09:13 | Aha, good newds, 1800 breached. Where next after bumping up here before (1790's)? Is it political certainty, is it cable...? Probably trade the break-out would be a good move. | ![]() sogoesit | |
18/12/2019 09:08 | Breakout!!! Yeeah baybee! | ![]() purplepelmets | |
17/12/2019 15:55 | Profit taking on the big gains yesterday obviously ;-) | abdullla | |
17/12/2019 15:27 | Large volumes traded today …. | tradermichael | |
17/12/2019 11:14 | @Lippy, hehe, indeed. Suspect Santa bounce is coming though so we might be disappointed! :) | ![]() crossing_the_rubicon | |
17/12/2019 11:11 | bit of luck it will go down first...lol | ![]() lippy4 | |
17/12/2019 10:55 | GlaxoSmithKline said on Monday it had applied for U.S. approval for its experimental multiple myeloma drug that showed meaningful response in nearly a third of patients, setting up a battle against Johnson & Johnson and Genmab's Darzalex. Those geezers at Jefferies raised TP 2000p - BUY | ![]() crossing_the_rubicon | |
16/12/2019 14:13 | Wasnt that Drug legislation championed by Trump??? "Trump has made a priority of trying to lower drug prices. But many of his most ardent supporters don’t know it" He certainly was talking about it in 2016 "President Trump is backing off his 2016 campaign pledge to negotiate drug prices for Medicare with pharmaceutical companies" The MSM though is painting it as Pelosi championing it..Which is partisan tosh. The Democrats have appended MORE elements to this bill which is why it seemingly wont pass the Republican controlled Senate.. | ![]() crossing_the_rubicon | |
16/12/2019 14:02 | By a 230-192 margin, the U.S. House of Representatives has passed legislation, championed by Speaker Nancy Pelosi, aimed at corralling spiralling drug costs. The bill's key provision would allow the feds to negotiate prices for expensive drugs that lack competition. A minimum of 50 medicines each year would be subject to talks. A last-minute addition was a feasibility study to extend rebates for drug prices that increase faster than inflation to employer-sponsored coverage. The bill has almost no chance to pass in the Republican-controlle | ![]() muscletrade | |
16/12/2019 13:10 | oooh you are awful!!!! | ![]() lippy4 | |
16/12/2019 13:03 | could not hold any longer so sold.. i thought being a dollar earner with the rising pound this share would suffer or is it the amalgamation thats keeping it up.. | ![]() lippy4 | |
16/12/2019 12:34 | I would sell half but keep the other half while sitting on the cash so earned,maybe :-)) | abdullla | |
16/12/2019 12:25 | If I don't sell, price would probably return to 1740p this afternoon. If I did sell, it would probably reach 1800p! LOL ….. ;0) | tradermichael | |
16/12/2019 12:21 | Its tempting, for me it would give a 19p profit (div) and a 19p gain (on the price) at 1775p, making £16K profit. | tradermichael | |
16/12/2019 12:00 | TM,Having crystallised your divi do you think its time to sell ? | abdullla |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions